Positive high-level results have been presented from the final overall survival (OS) analysis of the FLAURA2 Phase III trial.

AstraZeneca shares have dropped substantially from their record-breaking heyday in September, but is this the ideal time for me to buy more of them? The post Is it worth me buying more AstraZeneca ...

Azerbaijan Union of Film-makers (AUF) has announced the full-length feature film screenwriting contest titled "I Am a Woman", ...

Parker, who was wearing a distinctive black and grey track suit, forced the worker to open the till then grabbed handfuls of ...

Cammie, a young camel whose front leg was chopped off by a landlord in Pakistan’s southern province of Sindh, left her ...

J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.

Xelix, a leading agentic AI software company in the Accounts Payable (AP) space, today announced a $160 million Series B ...

UK stocks were struggling for direction on Monday, with the FTSE 100 continuing to test the elusive 9,000 level, though ...

The CBI adopted the SANA system for currency exchange offices, where one euro costs 834,029 rials and $1 costs 717,389 rials. NIMA is a scheme for selling a percentage of the foreign money earned from ...